Aims: We report updated results, with 9-months additional follow-up, in 1L patients who received olomorasib (a KRAS G12C inhibitor) + pembrolizumab from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01.
Methods: Patients with advanced KRAS G12C-mutant NSCLC (ECOG PS 0-1) and PD-L1 expression 0-100% were randomized to receive olomorasib 50 or 100 mg, orally BID with pembrolizumab 200 mg Q3W. Patients who received 1 cycle of pembrolizumab prior to enrollment were eligible. Primary endpoint: safety. Secondary endpoints: ORR per RECIST v1.1, DOR, and PFS.
Results: As of 5-March-2026, 85 patients received olomorasib + pembrolizumab (16% received 1 prior cycle of pembrolizumab; 64% were PD-L1 ≥50). The median follow-up time was 20.7 months (IQR,18.0-23.0). ORR was 73% in all patients (n=84; PD-L1 0-100%), 78% in patients with PD-L1 ≥50% (n=54). Responses were durable across all patients; median DOR and PFS were not reached, with a 6-, 12-, and 18-month PFS rate of 77%, 65% and 55%, respectively. No new safety signals were identified. Any-grade TRAEs (in ≥20% of patients): diarrhea (33%), ALT/AST increased (27%/25%). Most common grade ≥3 TRAEs: ALT/AST increased (16%/14%), diarrhea (8%). Hepatic events were manageable with dose adjustments and/or corticosteroids. TRAEs led to olomorasib dose reduction in 34% patients and discontinuation of combination treatment in 12%.
Conclusions: Olomorasib + pembrolizumab continues to demonstrate durable efficacy and a manageable safety profile. These updated findings provide additional support for the ongoing Phase 3 SUNRAY-01 trial, comparing pembrolizumab + olomorasib or placebo as 1L treatment in patients with KRAS G12C-mutant NSCLC and PD-L1 ≥50%.